Welcome to our dedicated page for CMNDF news (Ticker: CMNDF), a resource for investors and traders seeking the latest updates and insights on CMNDF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CMNDF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CMNDF's position in the market.
Clearmind Medicine Inc. has received patent approval from India for its MEAI-based alcohol substitute. This recognition follows similar patents granted in Europe, with pending applications in the U.S. and China. The company aims to tackle alcohol abuse through innovative treatments and food supplements. Clearmind holds several patents for its non-hallucinogenic compound, MEAI, and collaborates with Hebrew University and Bar Ilan University for research. Clearmind trades under CMND on the Canadian Securities Exchange and CMNDF on the OTC market.
Clearmind Medicine has successfully completed a pre-IND meeting with the FDA regarding its compound CMND-100, aimed at treating Alcohol Use Disorder (AUD). The FDA's feedback was constructive and encouraging, indicating potential support for the development program. Clearmind plans to initiate clinical trials for CMND-100 by the end of 2022. AUD affects over 18 million Americans, making CMND-100's development crucial. The company continues to focus on creating novel psychedelic-derived therapeutics to address significant health issues.
Clearmind Medicine Inc. (CMNDF) announced positive results from its joint pre-clinical trial with SciSparc Ltd. The trial evaluated the combination of Clearmind's MEAI and SciSparc's CannAmide™ for reducing alcohol consumption. Results showed a significant dose-dependent decrease in alcohol intake in mice, with a demonstrated high safety profile for the treatment. No treatment-related changes were observed in vital organs. Clearmind remains focused on developing psychedelic-derived therapeutics targeting health issues like alcohol use disorder.
Clearmind Medicine announced positive results from preclinical trials of its proprietary molecule MEAI, targeting alcohol abuse. Conducted on mice, the trials showed a significant reduction in alcohol consumption in groups treated with MEAI compared to the control group. Notably, no toxicological effects were observed in vital organs. These results support Clearmind's plans to advance to FDA-regulated clinical trials later this year. The company's focus remains on developing psychedelic-derived therapeutics to address alcohol use disorder and related mental health issues.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) has announced plans to meet with the FDA's Center for Drug Evaluation and Research on May 18, 2022. The purpose is to discuss the First in Human study for its drug candidate CMND-100 aimed at treating Alcohol Use Disorder (AUD). CEO Dr. Adi Zuloff-Shani emphasized this meeting is crucial for moving forward with clinical trials, expected to start by the end of 2022. CMND-100 targets a significant health issue, with AUD costing the U.S. $250 billion annually. The company holds patents for CMND-100 in multiple regions.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) announced a provisional patent application for a psychedelic combination therapy targeting binge behaviors, based on a successful pre-clinical trial. The study showed that MEAI, a novel psychedelic for addiction, significantly reduced alcohol consumption in mice. The combination with SciSparc's CannAmide™ further enhanced this effect. CEO Dr. Adi Zuloff-Shani emphasized the importance of expanding Clearmind's intellectual property portfolio in the industry.
Clearmind Medicine Inc. (CMNDF), a biotech company focusing on psychedelic-derived therapies, announced participation in the Psychedelic Capital virtual event on March 24, 2022. CEO Dr. Adi Zuloff-Shani and VP Mark Haden will present at a panel discussion at 1:45 PM EDT. The company aims to address health issues, particularly alcohol use disorder, through its research and development efforts. Clearmind's intellectual property portfolio consists of four patent families, with plans to seek additional patents to enhance its assets.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) reported positive results from two pre-clinical trials demonstrating the effectiveness of their psychedelic-based therapeutic CMND-100 in suppressing alcohol consumption in mice. The trials showed that doses of 40 mg/kg and higher significantly reduced alcohol intake compared to untreated controls. Additionally, combining lower doses of CMND-100 with CannAmide™ resulted in further reductions in alcohol consumption. These findings indicate potential for CMND-100 in treating alcohol use disorder and support Clearmind’s focus on developing novel psychedelic-derived therapeutics.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) announces a new collaboration with SciSparc Ltd. to explore the development of psychedelic-derived therapeutics. This partnership aims to create innovative compounds by integrating both companies' technologies through a joint pre-clinical study. CEO Adi Zuloff-Shani expressed excitement over the collaboration, emphasizing its potential impact on the mental health pharmaceutical market. The deal is categorized as a related party transaction, given the shared executive connections between the companies.
Clearmind Medicine Inc. (OTC Pink: CMNDF) will host a virtual event titled 'Psychedelics for Alcoholism' on February 23, 2022, at 12 p.m. EST, featuring market analyst Marissa Wright. The event aims to educate investors on psychedelic treatments for alcohol use disorder, building on increased interest following the pandemic. Clearmind's CEO, Adi Zuloff-Shani, emphasized the urgency of addressing alcoholism amid rising cases. This free event requires registration and is anticipated to attract significant viewership, following the success of their previous webinar with over 1200 attendees.
FAQ
What is the market cap of CMNDF (CMNDF)?
